Home Dr. Reddy Is Transitioning From A Pure Generic Player To An Innovator
 

Keywords :   


Dr. Reddy Is Transitioning From A Pure Generic Player To An Innovator

2016-02-18 00:09:33| Biotech - Topix.net

Currently it is just the warning letter that is at the top of everybody's mind when it comes to investing in Dr. Reddy. By 2022, Proprietary product business alone should contribute about INR 70 per share to the EPS.

Tags: to player pure generic

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
19.05 Dr. Squatch Launches Bronco Bricc
19.05Gillette Venus Announces Ambassadors Ahead of the Olympic and Paralympic Games Paris 2024
19.05Eastern North Pacific Tropical Weather Outlook
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
More »